Asthma and anaphylaxis are both recognised noncommunicable hypersensitivity disorders that should be carefully diagnosed and treated/controlled to reduce needless fatalities. The aim of this paper is to examine current and new evidence-based data on asthma and anaphylaxis in light of new understanding in the area that can promote quality practise and empower allergists and health workers in treating symptoms and preventing death. Life-threatening hypersensitivity illnesses, such as anaphylaxis and asthma, can coexist, imitate, or worsen one other. Asthma does not appear to be a strong predictor of more severe anaphylaxis. Poor asthma control, on the other hand, was linked to more severe anaphylactic events in people of all ages.
However, because this evaluation focuses on two important public health issues in the field of allergy, it is necessary to implement decisions that support suggestions in order to better manage afflicted individuals and reduce risk. Regular notification of this association, optimization of anaphylaxis classification and asthma coding should include general strategies to harmonise anaphylaxis stratified epidemiologic data, early diagnosis of childhood asthma, regular anaphylaxis examination and optimisation of the asthma control and lung performance for patients with provocative signals. Implementing this strategy will require national and international support to on-going efforts to provide tailored management to the most vulnerable patients in connection with networks of centres of excellence and avoid mortality.
Reference: https://journals.lww.com/co-allergy/Abstract/2019/10000/Asthma_and_anaphylaxis.7.aspx
